• 点赞
  • 评论
  • 收藏

Phathom Pharmaceuticals第四季度调整后每股收益$(0.79)优于预期$(1.27),销售额$29.66百万优于$24.91百万预期

财报速递2025-03-06

Phathom Pharmaceuticals(NASDAQ:PHAT)报告本季度每股亏损$(0.79),超过分析师共识预期的$(1.27),提高了37.8%。这比去年同期每股亏损$(0.80)增加了1.25%。公司报告本季度销售额为$29.66百万,超过分析师共识预期的$24.91百万,增长了19.09%。这比去年同期销售额$682,000增长了4,250%。

以上内容来自Benzinga Earnings专栏,原文如下:

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.27) by 37.8 percent. This is a 1.25 percent increase over losses of $(0.80) per share from the same period last year. The company reported quarterly sales of $29.66 million which beat the analyst consensus estimate of $24.91 million by 19.09 percent. This is a 4.25K percent increase over sales of $682.00 thousand the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论

empty
暂无评论
 
 
 
 

热议股票

 
 
 
 
 

7x24